Skip to Main Content
Table 1.

Current clinical strategies to target proteins of the Bcl-2 family

Drug Company Clinical phase Function Additional comments
ABT-263   Abbott Laboratories   Phase I and I/II clinical trials in NHL, CLL and SCLC   BH3-mimetic small molecule targeting Bcl-2, Bcl-XL and Bcl-w   ABT-263 is an orally available compound that is closely related to ABT-737  
Obatoclax (GX15-070)   Gemin X   Multiple phase I and II clinical trials in hematological malignancies and non-small-cell lung cancer   BH3-mimetic small molecule   Might be a pan-inhibitor of anti-apoptotic proteins  
Oblimersen   Genta   Many clinical trials including phase III in melanoma and CLL   Antisense DNA targeting Bcl-2   Clinical activity marginal, but not clear that drug is reducing Bcl-2 levels in vivo  
AT-101   Ascenta Therapeutics   Phase II clinical trials in a variety of cancers   BH3-mimetic small molecule   AT-101 is the negative enantiomer of gossypol  
Drug Company Clinical phase Function Additional comments
ABT-263   Abbott Laboratories   Phase I and I/II clinical trials in NHL, CLL and SCLC   BH3-mimetic small molecule targeting Bcl-2, Bcl-XL and Bcl-w   ABT-263 is an orally available compound that is closely related to ABT-737  
Obatoclax (GX15-070)   Gemin X   Multiple phase I and II clinical trials in hematological malignancies and non-small-cell lung cancer   BH3-mimetic small molecule   Might be a pan-inhibitor of anti-apoptotic proteins  
Oblimersen   Genta   Many clinical trials including phase III in melanoma and CLL   Antisense DNA targeting Bcl-2   Clinical activity marginal, but not clear that drug is reducing Bcl-2 levels in vivo  
AT-101   Ascenta Therapeutics   Phase II clinical trials in a variety of cancers   BH3-mimetic small molecule   AT-101 is the negative enantiomer of gossypol  

CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin's lymphoma; SCLC, small-cell lung cancer

Close Modal

or Create an Account

Close Modal
Close Modal